secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2026-07-24T12:31:43+00:00
Accession:  0001628280-26-049499
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Vir Bio CFO Jason O'Byrne to step down; Brent Sabatini named interim principal financial officer
--------------------------------------------------------------------------------

- CFO Jason O'Byrne resigns effective August 3, 2026, to pursue another opportunity; no disagreement with company.
- Board appoints Brent Sabatini, SVP and CAO, as interim principal financial officer effective same date.
- Sabatini has been CAO since Oct 2024, previously at Capsida and Amgen; no additional compensation for interim role.
- Search for permanent CFO initiated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000162828026049499/0001628280-26-049499-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000162828026049499/vir-20260720.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-049499

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer